Literature DB >> 12569589

Breast boost: are we missing the target?

Rashmi K Benda1, Gopika Yasuda, Anil Sethi, Sheryl G A Gabram, Russell W Hinerman, Nancy Price Mendenhall.   

Abstract

BACKGROUND: Randomized trials have shown improved local control with the use of a breast boost for patients given breast-conserving treatment for breast carcinoma. Although the use of a breast boost is routine practice, no standard technique has been established. The authors compared the commonly used clinical technique with a technique based on computed tomography (CT) imaging of surgical clips in the tumor bed.
METHODS: Thirty patients underwent CT simulation for postoperative radiation treatment planning as part of breast conservation therapy. During simulation, a CT-compatible wire was placed on the patient's skin, outlining the intended electron boost field; an electron boost volume (EBV) was generated by contouring the tissue underlying the wire. Also contoured was a CT-based clinical target volume (CTV) using surgical clips and postsurgical changes in the tumor bed as a guide. A planning target volume (PTV) was generated using a 1 cm margin around the CTV. An electron beam treatment plan was generated for each technique using the FOCUS three-dimensional treatment planning system. Dose-volume histograms (DVH) were generated to determine the fraction of the PTV receiving 90% of the prescribed dose if treatment was delivered using the EBV. In addition, DVH analysis was done to determine the volume of normal tissue unnecessarily irradiated when using the EBV.
RESULTS: Although the electron cone size remained unchanged in most patients for both EBV and PTV, the isocenter differed more than 1 cm in the medial-lateral direction in 5 patients and in the cephalocaudal direction in 12 patients. The en face gantry angle differed for most patients. On average, only 51% (range, 27-79%) of the PTV received 90% or more of the prescribed dose when the electron plan was generated using the EBV (P < 0.0001). Ten patients received the prescription dose to less than 50% of the PTV. Mean volume of normal tissue receiving more than 50% of prescribed dose was 64.5 cm(3) (range, 24-119 cm(3)).
CONCLUSIONS: Clinical delineation of the tumor bed not only carries a significant risk of missing the target, but unnecessarily treats breast tissue that may otherwise be spared. Better delineation of the tumor bed, which optimizes coverage of the target volume and spares normal breast tissue, has the potential to improve both local control and cosmetic outcome. The authors recommend the use of surgical clips to delineate the target volume, followed by CT-based treatment planning, accounting for not only microscopic disease, but also organ motion and daily setup error. Copyright 2003 American Cancer Society

Entities:  

Mesh:

Year:  2003        PMID: 12569589     DOI: 10.1002/cncr.11142

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Ten-year results of a phase II study with a single fraction of high-dose-rate brachytherapy (FAST-boost) after whole breast irradiation in invasive breast carcinoma.

Authors:  José Luis Guinot; M Isabel Tortajada; María Carrascosa; Vicente Crispín; Ana Otero; Belén Ríos; Eleonor Rivin; Miguel Santos; Pablo Soler; Leoncio Arribas
Journal:  Clin Transl Oncol       Date:  2012-02       Impact factor: 3.405

2.  Evaluation of adaptive radiotherapy (ART) by use of replanning the tumor bed boost with repeated computed tomography (CT) simulation after whole breast irradiation (WBI) for breast cancer patients having clinically evident seroma.

Authors:  Omer Sager; Ferrat Dincoglan; Bora Uysal; Selcuk Demiral; Hakan Gamsiz; Yelda Elcim; Esin Gundem; Bahar Dirican; Murat Beyzadeoglu
Journal:  Jpn J Radiol       Date:  2018-04-05       Impact factor: 2.374

Review 3.  Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date.

Authors:  G G Hanna; A M Kirby
Journal:  Br J Radiol       Date:  2015-03-03       Impact factor: 3.039

4.  Comparison of two radiation techniques for the breast boost in patients undergoing neoadjuvant treatment for breast cancer.

Authors:  Maria C De Santis; Luigia Nardone; Barbara Diletto; Roberta Canna; Michela Dispinzieri; Lorenza Marino; Laura Lozza; Vincenzo Valentini
Journal:  Br J Radiol       Date:  2016-07-25       Impact factor: 3.039

5.  Impact of a Novel Bioabsorbable Implant on Radiation Treatment Planning for Breast Cancer.

Authors:  Michael J Cross; Gail S Lebovic; Joseph Ross; Scott Jones; Arnold Smith; Steven Harms
Journal:  World J Surg       Date:  2017-02       Impact factor: 3.352

6.  Our intraoperative boost radiotherapy experience and applications.

Authors:  Semra Günay; Ömür Alan; Orhan Yalçın; Aygen Türkmen; Nihal Dizdar
Journal:  Ulus Cerrahi Derg       Date:  2015-06-24

Review 7.  Accelerated Partial Breast Irradiation (APBI): A review of available techniques.

Authors:  Christopher F Njeh; Mark W Saunders; Christian M Langton
Journal:  Radiat Oncol       Date:  2010-10-04       Impact factor: 3.481

8.  3D-conformal accelerated partial breast irradiation treatment planning: the value of surgical clips in the delineation of the lumpectomy cavity.

Authors:  Maia Dzhugashvili; Elodie Tournay; Charlotte Pichenot; Ariane Dunant; Eduardo Pessoa; Adel Khallel; Sébastien Gouy; Catherine Uzan; Jean-Rémy Garbay; Françoise Rimareix; Marc Spielmann; Philippe Vielh; Hugo Marsiglia; Céline Bourgier
Journal:  Radiat Oncol       Date:  2009-12-31       Impact factor: 3.481

9.  Semi-Supervised Deep Learning-Based Image Registration Method with Volume Penalty for Real-Time Breast Tumor Bed Localization.

Authors:  Marek Wodzinski; Izabela Ciepiela; Tomasz Kuszewski; Piotr Kedzierawski; Andrzej Skalski
Journal:  Sensors (Basel)       Date:  2021-06-14       Impact factor: 3.576

10.  Volumetric changes in the lumpectomy cavity during whole breast irradiation after breast conserving surgery.

Authors:  Heunglae Cho; Cheoljin Kim
Journal:  Radiat Oncol J       Date:  2011-12-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.